The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

By S. Mirra, A. Heyman, D. McKeel, S. Sumi, B. Crain, L. Brownlee, F. Vogel, J. Hughes, G. Belle, L. Berg and 22 more. 1991

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Interpretable classification of Alzheimer’s disease pathologies with a convolutional neural network pipeline (2018, methodology): “Consequently, studies using limited-range scores or overall pathology burden 3,8,13,24 are powerful but have interrater variability, 4,13 are difficult to adapt to statistically meaningful disease-correlation analysis, or are blind to selected locational vulnerability 20 .”
Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries. (2002, unknown): “Following the initial development of the CERAD clinical and neuropsychological batteries, CERAD has also standardized neuropathological assessment (Mirra et al., 1991), neuroimaging evaluation (Davis et al., 1992), and rating for behavioral symptoms of dementia (Tariot et al., 1995).”
Mitochondrial Abnormalities in Alzheimer's Disease (2001, methodology): “Brain tissue was obtained at autopsy from cases with a diagnosis of AD (Khachaturian, 1985; Mirra et al., 1991) as well as control cases with no clinical or pathological history of neurological disease.”
CHRONIC TRAUMATIC ENCEPHALOPATHY IN A NATIONAL FOOTBALL LEAGUE PLAYER: PART II (2005, methodology): “The determination of the density of NFTs and NTs was adapted from the density distribution of neuritic plaques by the Consortium to Establish a Registry for Alzheimer’s Disease, which is used for the neuropathological diagnosis of Alzheimer’s disease (9, 12, 23).”
Macroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease (2005, methodology): “Seven of these cases (aged 71–86 yr) were later found to meet the neuropathological criteria of AD (Braak and Braak, 1991; Mirra et al., 1991, 1993; Newell et al., 1999), and the remaining three specimens (aged 67–72 yr) were found to be neuropathologically normal (Wegiel et al., 2000).”
Variation in hippocampal neuron number with age and brain volume. (1998, unknown): “Pathological examination demonstrated that no case fulfilled the criteria for a diagnosis of Alzheimer's disease (Tierney et al., 1988; Mirra et al., 1991).”